

Маркетинговое агентство

S D A

Телефон: +7 (812) 209-45-37
+7 (911) 925-45-37
E-mail: sda@sdamarketing.ru
<https://sdamarketing.ru/>

Демонстрационная версия

**Маркетинговое исследование рынка CLT-
панелей**

г. Санкт-Петербург

Оглавление

1.	Описание рынка	4
2.	Объем российского и мирового рынка	8
2.1.	Рынок CLT-панелей Европы	8
2.2.	Рынок CLT-панелей России	9
3.	Ключевые факторы и тенденции рынка	11
4.	Оценка эластичности и сезонности спроса	13
4.1.	Эластичность спроса на CLT-панели	13
4.2.	Сезонность спроса на CLT-панели	13
5.	Анализ конкурентной среды.....	15
5.1.	Конкуренция на российской рынке	15
5.1.1.	Характеристики крупнейших производителей CLT-панелей	16
	Sokol CLT.....	16
	ООО «Промстройлес плюс»	16
5.2.	Конкуренция на европейском рынке.....	17
5.2.1.	Характеристики крупнейших европейских производителей CLT-панелей.....	18
	StoraEnso	18
	KLH	18
	Binderholz.....	18
	Mayr Melnhof	18
	Hasslacher	19
6.	Факторы конкуренции на рынке	20
7.	Обзор сырьевой базы.....	24
8.	Средние цены и принципы ценообразования	25
9.	Оценка инвестиционной привлекательности рынка	27
10.	Оценка рисков и мероприятия по снижению рисков	29

Список таблиц, диаграмм и рисунков

Таблица 1. Сравнение характеристик CLT-панелей с аналогами	5
Рисунок 1. Сравнение технологий строительства	6
Диаграмма 1. Введено в действие общей площади построенных населением жилых домов (в т.ч. в садоводствах), млн. кв.м.....	6
Диаграмма 2. Структура ввода в действие жилых домов по типам конструкционных материалов, млн. кв.м.	6
Диаграмма 3. Структура применения технологий в деревянном домостроении	7
Диаграмма 4. Структура производства CLT-панелей по странам Европы	8
Диаграмма 5. Динамика объема рынка CLT-панелей в Европе, тыс. м ³	8
Диаграмма 6. Динамика объема рынка CLT-панелей в РФ, тыс. м ³	9
Диаграмма 7. Динамика экспорта CLT-панелей из РФ, тыс. м ³	10
Диаграмма 8. Структура экспорта слоисто-клееного стройматериала из РФ по странам, тыс. м ³	10
Рисунок 2. Жизненный цикл древесных плит и аналогичной продукции	10
Диаграмма 9. Динамика производства пиломатериалов в РФ, тыс. м ³	11
Диаграмма 10. Динамика средних цен на пиломатериалы в РФ, руб/м ³	11
Диаграмма 11. Отгружено товаров деревянных плит и панелей по РФ, в рублях	13
Диаграмма 12. Введено в действие жилых домов, построенных населением, млн. м ²	14
Диаграмма 13. Оценка динамики рыночной доли российских компаний производителей CLT-панелей	15
Таблица 2. Производственные мощности российских производителей CLT-панелей	15
Таблица 3. Сравнительные характеристики продукции российских производителей CLT-панелей, трехслойных плит	15
Таблица 4. Основные финансовые показатели деятельности ООО Сокол СиЭлТи, млн. руб.	16
Таблица 5. Основные финансовые показатели деятельности АО С-ДОК, млн. руб.....	16
Таблица 6. Основные финансовые показатели деятельности ООО Промстройлес плюс, млн. руб.	17
Таблица 7. Основные финансовые показатели деятельности ООО Георг Наст, млн. руб.	17
Диаграмма 14. Мощности ведущих производителей клееной строительной древесины в Европе по видам	17
Таблица 8. Производственные мощности крупнейших европейских компаний – производителей CLT-панелей	17
Таблица 9. Основные финансовые показатели деятельности Stora Enso, млн. \$ США	18
Таблица 10. Основные финансовые показатели деятельности KLH MassivholzGmbH, млн. \$ США	18
Таблица 11. Основные финансовые показатели деятельности Binderholz, млн. \$ США	18
Таблица 12. Основные финансовые показатели деятельности Mayr Melnhof, млн. \$ США	18
Таблица 13. Основные финансовые показатели деятельности Hasslacher, млн. \$ США	19
Таблица 16. Структура европейского рынка. Условия конкуренции	20
Таблица 14. Сравнительные характеристики продукции европейских производителей CLT-панелей	21
Диаграмма 15. Структура расходов на производство	24
Таблица 15. Ценовое предложение отечественных производителей CLT-панелей и поперечно-клееных плит, руб./м ²	25
Диаграмма 16. Средние цена на необработанные CLT-панели в Европе	25
Таблица 16. Динамика рыночных цен на CLT-панели толщиной 19 мм	25
Таблица 17. Оценка факторов инвестиционной привлекательности рынка CLT-панелей	28
Таблица 18. Матрица рисков Объекта на внутреннем рынке	29
Таблица 19. Матрица рисков Объекта при экспортных поставках	29
Таблица 20. Матрица технологических рисков и инструменты снижения	29



Category	Type	Sub-Type	Performance Metrics	
			Mean	SD
1	1	1	0.85	0.05
1	1	2	0.88	0.04
1	2	1	0.82	0.06
1	2	2	0.87	0.03
2	1	1	0.78	0.07
2	1	2	0.80	0.05
2	2	1	0.75	0.08
2	2	2	0.79	0.04
3	1	1	0.72	0.09
3	1	2	0.74	0.06
3	2	1	0.68	0.10
3	2	2	0.73	0.05
4	1	1	0.65	0.12
4	1	2	0.67	0.08
4	2	1	0.62	0.13
4	2	2	0.66	0.07
5	1	1	0.58	0.15
5	1	2	0.60	0.10
5	2	1	0.55	0.16
5	2	2	0.59	0.09
6	1	1	0.50	0.18
6	1	2	0.52	0.12
6	2	1	0.47	0.19
6	2	2	0.51	0.11
7	1	1	0.42	0.20
7	1	2	0.44	0.14
7	2	1	0.40	0.21
7	2	2	0.44	0.13
8	1	1	0.35	0.22
8	1	2	0.37	0.16
8	2	1	0.33	0.23
8	2	2	0.37	0.15
9	1	1	0.28	0.24
9	1	2	0.30	0.18
9	2	1	0.26	0.25
9	2	2	0.30	0.17
10	1	1	0.20	0.26
10	1	2	0.22	0.20
10	2	1	0.18	0.27
10	2	2	0.22	0.19
11	1	1	0.12	0.28
11	1	2	0.14	0.22
11	2	1	0.10	0.29
11	2	2	0.14	0.21
12	1	1	0.05	0.30
12	1	2	0.07	0.24
12	2	1	0.03	0.31
12	2	2	0.07	0.23

the first time, the results of the study were presented at the 2013 Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA. The meeting was attended by approximately 15,000 hematologists and other medical professionals from around the world.

The study, titled "A phase I study of the safety and pharmacokinetics of lenalidomide in patients with multiple myeloma," was presented by Dr. Richard Crowley, a hematologist at the University of Texas MD Anderson Cancer Center in Houston, TX.

The study involved 12 patients with multiple myeloma who received lenalidomide at various doses. The patients were followed for up to 12 months, and their responses to the drug were evaluated.

The results showed that lenalidomide was well-tolerated at all doses tested, and that it had a similar safety profile to that seen in previous studies of lenalidomide in other types of cancer.

The study also found that lenalidomide was effective in some patients with multiple myeloma, particularly those who had previously been treated with other drugs.

Overall, the results of this study suggest that lenalidomide may be a promising new treatment option for patients with multiple myeloma.

Dr. Crowley concluded the presentation by stating that "this study provides important information about the safety and efficacy of lenalidomide in patients with multiple myeloma, and we hope that it will help guide future clinical trials of this drug in this disease."

The study was funded by Celgene Corporation, the manufacturer of lenalidomide. The results of the study were presented at the 2013 Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

The study involved 12 patients with multiple myeloma who received lenalidomide at various doses. The patients were followed for up to 12 months, and their responses to the drug were evaluated.

The results showed that lenalidomide was well-tolerated at all doses tested, and that it had a similar safety profile to that seen in previous studies of lenalidomide in other types of cancer.

The study also found that lenalidomide was effective in some patients with multiple myeloma, particularly those who had previously been treated with other drugs.

Overall, the results of this study suggest that lenalidomide may be a promising new treatment option for patients with multiple myeloma.

Dr. Crowley concluded the presentation by stating that "this study provides important information about the safety and efficacy of lenalidomide in patients with multiple myeloma, and we hope that it will help guide future clinical trials of this drug in this disease."

The study was funded by Celgene Corporation, the manufacturer of lenalidomide. The results of the study were presented at the 2013 Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

The study involved 12 patients with multiple myeloma who received lenalidomide at various doses. The patients were followed for up to 12 months, and their responses to the drug were evaluated.

The results showed that lenalidomide was well-tolerated at all doses tested, and that it had a similar safety profile to that seen in previous studies of lenalidomide in other types of cancer.

The study also found that lenalidomide was effective in some patients with multiple myeloma, particularly those who had previously been treated with other drugs.

Overall, the results of this study suggest that lenalidomide may be a promising new treatment option for patients with multiple myeloma.

Dr. Crowley concluded the presentation by stating that "this study provides important information about the safety and efficacy of lenalidomide in patients with multiple myeloma, and we hope that it will help guide future clinical trials of this drug in this disease."

1. The following table shows the results of a survey of 1000 people about their favorite type of music. Complete the table.



2. A school has 1200 students. 40% of the students are in the 9th grade. The remaining students are split evenly between the 10th and 11th grades. How many students are in each of the three grades?

3. A company has 1500 employees. 30% of the employees are men. The remaining employees are split evenly between women and children. How many men, women, and children are there?

4. A store has 1000 items in stock. 20% of the items are sold. The remaining items are split evenly between new arrivals and old stock. How many new arrivals, old stock, and sold items are there?

5. A factory produces 1500 units of a product. 30% of the units are sold. The remaining units are split evenly between new models and old models. How many new models, old models, and sold units are there?




6. A library has 1200 books. 40% of the books are fiction. The remaining books are split evenly between non-fiction and classics. How many fiction, non-fiction, and classics books are there?

7. A company has 1500 employees. 30% of the employees are men. The remaining employees are split evenly between women and children. How many men, women, and children are there?

8. A store has 1000 items in stock. 20% of the items are sold. The remaining items are split evenly between new arrivals and old stock. How many new arrivals, old stock, and sold items are there?

9. A factory produces 1500 units of a product. 30% of the units are sold. The remaining units are split evenly between new models and old models. How many new models, old models, and sold units are there?

10. A library has 1200 books. 40% of the books are fiction. The remaining books are split evenly between non-fiction and classics. How many fiction, non-fiction, and classics books are there?



1.1.1. *Protein expression*

The protein expression was performed in *Saccharomyces cerevisiae* using the pET28a(+) vector (Novagen) containing the target gene under the control of the *T7lacZ* promoter. The yeast strain used was *S. cerevisiae* BY4741 (Open Biosystems). The expression construct was transformed into yeast cells using the standard yeast transformation protocol (Gietz et al., 1992). The transformants were selected on YPD medium (1% yeast extract, 2% peptone, 2% dextrose) and grown overnight at 30 °C. The culture was then diluted 1:100 in YPD medium and grown for 4 h at 30 °C. The culture was then induced with 0.05 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h at 30 °C. The culture was then harvested and washed with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄) and lysed by sonication.

The supernatant was collected and stored at -20 °C until further analysis.



The protein expression was analyzed by SDS-PAGE gel electrophoresis. The SDS-PAGE gel was run on a 12% acrylamide gel and stained with Coomassie Blue R-250 (Sigma-Aldrich). The protein bands were visualized using a Bio-Rad Gel Doc system and quantified using the ImageJ software (NIH).

The results showed that the protein expression levels increased significantly from sample S1 to S8, with S8 showing the highest expression level.

The protein expression levels are summarized in Table 1. The results show that the protein expression levels increased significantly from sample S1 to S8, with S8 showing the highest expression level.

Table 1. Protein expression levels across different samples.

The protein expression levels are summarized in Table 1. The results show that the protein expression levels increased significantly from sample S1 to S8, with S8 showing the highest expression level.

The protein expression levels are summarized in Table 1. The results show that the protein expression levels increased significantly from sample S1 to S8, with S8 showing the highest expression level.

The protein expression levels are summarized in Table 1. The results show that the protein expression levels increased significantly from sample S1 to S8, with S8 showing the highest expression level.

The protein expression levels are summarized in Table 1. The results show that the protein expression levels increased significantly from sample S1 to S8, with S8 showing the highest expression level.

Figure 1. Summary of the main results





1920-1921
1921-1922
1922-1923
1923-1924
1924-1925
1925-1926
1926-1927
1927-1928
1928-1929
1929-1930
1930-1931
1931-1932
1932-1933
1933-1934
1934-1935
1935-1936
1936-1937
1937-1938
1938-1939
1939-1940
1940-1941
1941-1942
1942-1943
1943-1944
1944-1945
1945-1946
1946-1947
1947-1948
1948-1949
1949-1950
1950-1951
1951-1952
1952-1953
1953-1954
1954-1955
1955-1956
1956-1957
1957-1958
1958-1959
1959-1960
1960-1961
1961-1962
1962-1963
1963-1964
1964-1965
1965-1966
1966-1967
1967-1968
1968-1969
1969-1970
1970-1971
1971-1972
1972-1973
1973-1974
1974-1975
1975-1976
1976-1977
1977-1978
1978-1979
1979-1980
1980-1981
1981-1982
1982-1983
1983-1984
1984-1985
1985-1986
1986-1987
1987-1988
1988-1989
1989-1990
1990-1991
1991-1992
1992-1993
1993-1994
1994-1995
1995-1996
1996-1997
1997-1998
1998-1999
1999-2000
2000-2001
2001-2002
2002-2003
2003-2004
2004-2005
2005-2006
2006-2007
2007-2008
2008-2009
2009-2010
2010-2011
2011-2012
2012-2013
2013-2014
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
2025-2026
2026-2027
2027-2028
2028-2029
2029-2030
2030-2031
2031-2032
2032-2033
2033-2034
2034-2035
2035-2036
2036-2037
2037-2038
2038-2039
2039-2040
2040-2041
2041-2042
2042-2043
2043-2044
2044-2045
2045-2046
2046-2047
2047-2048
2048-2049
2049-2050
2050-2051
2051-2052
2052-2053
2053-2054
2054-2055
2055-2056
2056-2057
2057-2058
2058-2059
2059-2060
2060-2061
2061-2062
2062-2063
2063-2064
2064-2065
2065-2066
2066-2067
2067-2068
2068-2069
2069-2070
2070-2071
2071-2072
2072-2073
2073-2074
2074-2075
2075-2076
2076-2077
2077-2078
2078-2079
2079-2080
2080-2081
2081-2082
2082-2083
2083-2084
2084-2085
2085-2086
2086-2087
2087-2088
2088-2089
2089-2090
2090-2091
2091-2092
2092-2093
2093-2094
2094-2095
2095-2096
2096-2097
2097-2098
2098-2099
2099-20100





10.000
8.000
6.000
4.000
2.000
0.000



10.000
8.000
6.000
4.000
2.000
0.000

10.000
8.000
6.000
4.000
2.000
0.000

10.000
8.000
6.000
4.000
2.000
0.000

Year	Population	Area (km²)	Population Density (people/km²)
1950	1500000	1500	1000
1960	2000000	1500	1333
1970	2500000	1500	1667
1980	3000000	1500	2000
1990	3500000	1500	2333
2000	4000000	1500	2667
2010	4500000	1500	3000
2020	5000000	1500	3333
2030	5500000	1500	3667
2040	6000000	1500	4000
2050	6500000	1500	4333
2060	7000000	1500	4667
2070	7500000	1500	5000
2080	8000000	1500	5333
2090	8500000	1500	5667
2100	9000000	1500	6000

Category	Type	Title	Author	Score		Notes
				Score	Rank	
Books	Book	The Great Gatsby	F. Scott Fitzgerald	95	1	
Books	Book	1984	George Orwell	90	2	
Books	Book	To Kill a Mockingbird	Harper Lee	88	3	
Books	Book	Pride and Prejudice	Jane Austen	85	4	
Books	Book	The Catcher in the Rye	J. D. Salinger	82	5	
Books	Book	One Hundred Years of Solitude	Gabriel García Márquez	80	6	
Books	Book	The Lord of the Rings	J. R. R. Tolkien	78	7	
Books	Book	Brave New World	George Orwell	75	8	
Books	Book	The Hobbit	J. R. R. Tolkien	72	9	
Books	Book	War and Peace	Leo Tolstoy	70	10	
Short Stories	Story	The Metamorphosis	Franz Kafka	92	1	
Short Stories	Story	The Short Happy Life of Francis Macomber	O. Henry	90	2	
Short Stories	Story	The Rocking-Horse Winner	D. H. Lawrence	88	3	
Short Stories	Story	The Lottery	Shirley Jackson	85	4	
Short Stories	Story	The Most Dangerous Game	Richard Matheson	82	5	
Short Stories	Story	The Tell-Tale Heart	Edgar Allan Poe	80	6	
Short Stories	Story	The Yellow Wall-Paper	Susan Glaspell	78	7	
Short Stories	Story	The Lesson	Barry Hirschfeld	75	8	
Short Stories	Story	The Last Leaf	O. Henry	72	9	
Short Stories	Story	The Death of Ivan Ilyich	Leo Tolstoy	70	10	
Newspapers	Newspaper	The New York Times	Various	98	1	
Newspapers	Newspaper	The Washington Post	Various	95	2	
Newspapers	Newspaper	USA Today	Various	90	3	
Newspapers	Newspaper	The Wall Street Journal	Various	88	4	
Newspapers	Newspaper	The Guardian	Various	85	5	
Newspapers	Newspaper	The Independent	Various	82	6	
Newspapers	Newspaper	The New Yorker	Various	80	7	
Newspapers	Newspaper	The Atlantic	Various	78	8	
Newspapers	Newspaper	The Economist	Various	75	9	
Newspapers	Newspaper	The BBC News	Various	72	10	
Movies	Movie	The Godfather	Francis Ford Coppola	95	1	
Movies	Movie	The Shawshank Redemption	Frank Darabont	90	2	
Movies	Movie	The Dark Knight	Christopher Nolan	88	3	
Movies	Movie	Star Wars: Episode V - The Empire Strikes Back	George Lucas	85	4	
Movies	Movie	The Godfather: Part II	Francis Ford Coppola	82	5	
Movies	Movie	Seven	Sam Peckinpah	80	6	
Movies	Movie	The Good, the Bad and the Ugly	Ugo Tognazzi	78	7	
Movies	Movie	Butch Cassidy and the Sundance Kid	George Roy Hill	75	8	
Movies	Movie	The Silence of the Lambs	Jonathan Demme	72	9	
Movies	Movie	The Seven Samurai	Akira Kurosawa	70	10	
TV Shows	TV Show	Breaking Bad	Alan Cranston	95	1	
TV Shows	TV Show	Game of Thrones	Peter Dinklage	90	2	
TV Shows	TV Show	House	Gregory House	88	3	
TV Shows	TV Show	Stranger Things	Eleven	85	4	
TV Shows	TV Show	The Wire	Raymond Polk	82	5	
TV Shows	TV Show	True Blood	Anna Paquin	80	6	
TV Shows	TV Show	Mad Men	Don Draper	78	7	
TV Shows	TV Show	BoJack Horseman	BoJack Horseman	75	8	
TV Shows	TV Show	Breaking Bad	Walter White	72	9	
TV Shows	TV Show	The Sopranos	Tony Soprano	70	10	
Documentaries	Documentary	The Godfather: Part III	Francis Ford Coppola	95	1	
Documentaries	Documentary	The Last Castle	Mike Nichols	90	2	
Documentaries	Documentary	The Godfather: Part I	Francis Ford Coppola	88	3	
Documentaries	Documentary	The Godfather: Part II	Francis Ford Coppola	85	4	
Documentaries	Documentary	The Godfather: Part III	Francis Ford Coppola	82	5	
Documentaries	Documentary	The Godfather: Part I	Francis Ford Coppola	80	6	
Documentaries	Documentary	The Godfather: Part II	Francis Ford Coppola	78	7	
Documentaries	Documentary	The Godfather: Part III	Francis Ford Coppola	75	8	
Documentaries	Documentary	The Godfather: Part I	Francis Ford Coppola	72	9	
Documentaries	Documentary	The Godfather: Part II	Francis Ford Coppola	70	10	

X	Y	Z	A		B	
			C	D	E	F
1	1	1	1	1	1	1
2	2	2	2	2	2	2
3	3	3	3	3	3	3
4	4	4	4	4	4	4
5	5	5	5	5	5	5
6	6	6	6	6	6	6
7	7	7	7	7	7	7
8	8	8	8	8	8	8
9	9	9	9	9	9	9
10	10	10	10	10	10	10
11	11	11	11	11	11	11
12	12	12	12	12	12	12
13	13	13	13	13	13	13
14	14	14	14	14	14	14
15	15	15	15	15	15	15
16	16	16	16	16	16	16
17	17	17	17	17	17	17
18	18	18	18	18	18	18
19	19	19	19	19	19	19
20	20	20	20	20	20	20
21	21	21	21	21	21	21
22	22	22	22	22	22	22
23	23	23	23	23	23	23
24	24	24	24	24	24	24
25	25	25	25	25	25	25
26	26	26	26	26	26	26
27	27	27	27	27	27	27
28	28	28	28	28	28	28
29	29	29	29	29	29	29
30	30	30	30	30	30	30
31	31	31	31	31	31	31
32	32	32	32	32	32	32
33	33	33	33	33	33	33
34	34	34	34	34	34	34
35	35	35	35	35	35	35
36	36	36	36	36	36	36
37	37	37	37	37	37	37
38	38	38	38	38	38	38
39	39	39	39	39	39	39
40	40	40	40	40	40	40
41	41	41	41	41	41	41
42	42	42	42	42	42	42
43	43	43	43	43	43	43
44	44	44	44	44	44	44
45	45	45	45	45	45	45
46	46	46	46	46	46	46
47	47	47	47	47	47	47
48	48	48	48	48	48	48
49	49	49	49	49	49	49
50	50	50	50	50	50	50
51	51	51	51	51	51	51
52	52	52	52	52	52	52
53	53	53	53	53	53	53
54	54	54	54	54	54	54
55	55	55	55	55	55	55
56	56	56	56	56	56	56
57	57	57	57	57	57	57
58	58	58	58	58	58	58
59	59	59	59	59	59	59
60	60	60	60	60	60	60
61	61	61	61	61	61	61
62	62	62	62	62	62	62
63	63	63	63	63	63	63
64	64	64	64	64	64	64
65	65	65	65	65	65	65
66	66	66	66	66	66	66
67	67	67	67	67	67	67
68	68	68	68	68	68	68
69	69	69	69	69	69	69
70	70	70	70	70	70	70
71	71	71	71	71	71	71
72	72	72	72	72	72	72
73	73	73	73	73	73	73
74	74	74	74	74	74	74
75	75	75	75	75	75	75
76	76	76	76	76	76	76
77	77	77	77	77	77	77
78	78	78	78	78	78	78
79	79	79	79	79	79	79
80	80	80	80	80	80	80
81	81	81	81	81	81	81
82	82	82	82	82	82	82
83	83	83	83	83	83	83
84	84	84	84	84	84	84
85	85	85	85	85	85	85
86	86	86	86	86	86	86
87	87	87	87	87	87	87
88	88	88	88	88	88	88
89	89	89	89	89	89	89
90	90	90	90	90	90	90
91	91	91	91	91	91	91
92	92	92	92	92	92	92
93	93	93	93	93	93	93
94	94	94	94	94	94	94
95	95	95	95	95	95	95
96	96	96	96	96	96	96
97	97	97	97	97	97	97
98	98	98	98	98	98	98
99	99	99	99	99	99	99
100	100	100	100	100	100	100



Year	Population (in millions)
1900	13.8
1910	15.1
1920	17.0
1930	19.3
1940	22.1
1950	25.5
1960	30.1
1970	37.0
1980	43.7
1990	49.7
2000	52.7
2010	54.4
2020	55.9

Category	Sub-Categories	Product Details	Quantity	Unit Price	Total Value
Electronics	Smartphones, Laptops, Tablets	High-end devices with advanced features.	100	\$1000-\$2000	\$100,000-\$200,000
Home Appliances	Refrigerators, Washers, Dryers	Energy-efficient models with modern designs.	50	\$500-\$1000	\$25,000-\$50,000
Automotive	Cars, SUVs, Electric Vehicles	Various models ranging from compact to luxury vehicles.	30	\$20,000-\$50,000	\$600,000-\$1,500,000
Leisure	Gaming Consoles, VR Headsets, Sports Equipment	Entertainment and physical activity products.	20	\$100-\$1000	\$20,000-\$20,000
Business & Office	Computers, Software, Office Supplies	Tools for professional and administrative work.	40	\$50-\$500	\$20,000-\$20,000
Healthcare	Medical Devices, Health Supplements, Personal Care	Products for maintaining physical and mental well-being.	30	\$10-\$100	\$3,000-\$3,000
Food & Beverage	Groceries, Dining Out, Special Occasions	Items for eating and drinking.	60	\$5-\$50	\$3,000-\$3,000
Travel	Airline Tickets, Hotel Accommodations, Travel Gear	Services and products for journeys.	15	\$100-\$1000	\$1,500-\$1,500
Personal Care	Haircare, Skincare, Cosmetics	Products for personal grooming.	25	\$10-\$100	\$2,500-\$2,500
Books & Media	Physical Books, E-books, Movies, Music	Entertainment and educational materials.	35	\$5-\$50	\$1,750-\$1,750
Gifts & Merchandise	Customized Items, Special Editions, Collectibles	Items given as gifts or souvenirs.	10	\$100-\$1000	\$1,000-\$1,000
Industrial	Machinery, Tools, Equipment	Products used in commercial settings.	5	\$1000-\$10,000	\$5,000-\$5,000
Other	Surveillance Systems, Security Equipment, Industrial Components	Specialty items for specific industries.	2	\$1000-\$10,000	\$2,000-\$2,000





• 100% of respondents said that they had been asked to do something that they did not feel comfortable doing at work.

• 100% of respondents said that they had been asked to do something that they did not feel comfortable doing at work.

• 100% of respondents said that they had been asked to do something that they did not feel comfortable doing at work.



• 100% of respondents said that they had been asked to do something that they did not feel comfortable doing at work.

• 100% of respondents said that they had been asked to do something that they did not feel comfortable doing at work.

• 100% of respondents said that they had been asked to do something that they did not feel comfortable doing at work.







Category	Sub-Category	Item Description	Quantity	Unit Price	Total Value
Electronics	Smartphones	iPhone 12 Pro Max	10	\$1,000	\$10,000
Electronics	Smartphones	Samsung Galaxy S21 Ultra	15	\$900	\$13,500
Electronics	Laptops	Dell XPS 15	8	\$1,200	\$9,600
Electronics	Laptops	HP Spectre x360	7	\$1,100	\$7,700
Electronics	Tablets	Apple iPad Pro 12.9"	5	\$800	\$4,000
Electronics	Tablets	Samsung Galaxy Tab S7+	6	\$700	\$4,200
Peripherals	Monitors	Dell U2720Q	12	\$400	\$4,800
Peripherals	Keyboards	Razer BlackWidow	10	\$150	\$1,500
Peripherals	Mice	Logitech G903	15	\$100	\$1,500
Peripherals	Speakers	JBL Quantum 2.1	8	\$120	\$960
Peripherals	Power Banks	Anker PowerCore 20100	20	\$50	\$1,000
Peripherals	USB Drives	Western Digital My Passport	10	\$30	\$300
Software	Operating Systems	Windows 10 Pro	15	\$150	\$2,250
Software	Office Suites	Microsoft Office 365	10	\$200	\$2,000
Software	Productivity Tools	Google Workspace	8	\$180	\$1,440
Software	Design Software	Adobe Creative Cloud	5	\$300	\$1,500
Software	Security Software	McAfee Total Protection	20	\$25	\$500
Software	Cloud Storage	Dropbox Business	12	\$100	\$1,200
Software	Virtualization	VMware Workstation	7	\$250	\$1,750
Software	Cloud Computing	AWS Developer Preview	3	\$500	\$1,500
Software	Machine Learning	TensorFlow	2	\$1,000	\$2,000
Software	Big Data	Hadoop	1	\$2,000	\$2,000
Software	Blockchain	Ethereum	1	\$3,000	\$3,000
Software	Cloud Computing	Microsoft Azure	1	\$4,000	\$4,000
Software	Machine Learning	TensorFlow	1	\$5,000	\$5,000
Software	Big Data	Hadoop	1	\$6,000	\$6,000
Software	Blockchain	Ethereum	1	\$7,000	\$7,000
Software	Cloud Computing	Amazon Web Services	1	\$8,000	\$8,000
Software	Machine Learning	TensorFlow	1	\$9,000	\$9,000
Software	Big Data	Hadoop	1	\$10,000	\$10,000
Software	Blockchain	Ethereum	1	\$11,000	\$11,000
Software	Cloud Computing	Microsoft Azure	1	\$12,000	\$12,000
Software	Machine Learning	TensorFlow	1	\$13,000	\$13,000
Software	Big Data	Hadoop	1	\$14,000	\$14,000
Software	Blockchain	Ethereum	1	\$15,000	\$15,000
Software	Cloud Computing	Amazon Web Services	1	\$16,000	\$16,000
Software	Machine Learning	TensorFlow	1	\$17,000	\$17,000
Software	Big Data	Hadoop	1	\$18,000	\$18,000
Software	Blockchain	Ethereum	1	\$19,000	\$19,000
Software	Cloud Computing	Microsoft Azure	1	\$20,000	\$20,000
Software	Machine Learning	TensorFlow	1	\$21,000	\$21,000
Software	Big Data	Hadoop	1	\$22,000	\$22,000
Software	Blockchain	Ethereum	1	\$23,000	\$23,000
Software	Cloud Computing	Amazon Web Services	1	\$24,000	\$24,000
Software	Machine Learning	TensorFlow	1	\$25,000	\$25,000
Software	Big Data	Hadoop	1	\$26,000	\$26,000
Software	Blockchain	Ethereum	1	\$27,000	\$27,000
Software	Cloud Computing	Microsoft Azure	1	\$28,000	\$28,000
Software	Machine Learning	TensorFlow	1	\$29,000	\$29,000
Software	Big Data	Hadoop	1	\$30,000	\$30,000
Software	Blockchain	Ethereum	1	\$31,000	\$31,000
Software	Cloud Computing	Amazon Web Services	1	\$32,000	\$32,000
Software	Machine Learning	TensorFlow	1	\$33,000	\$33,000
Software	Big Data	Hadoop	1	\$34,000	\$34,000
Software	Blockchain	Ethereum	1	\$35,000	\$35,000
Software	Cloud Computing	Microsoft Azure	1	\$36,000	\$36,000
Software	Machine Learning	TensorFlow	1	\$37,000	\$37,000
Software	Big Data	Hadoop	1	\$38,000	\$38,000
Software	Blockchain	Ethereum	1	\$39,000	\$39,000
Software	Cloud Computing	Amazon Web Services	1	\$40,000	\$40,000
Software	Machine Learning	TensorFlow	1	\$41,000	\$41,000
Software	Big Data	Hadoop	1	\$42,000	\$42,000
Software	Blockchain	Ethereum	1	\$43,000	\$43,000
Software	Cloud Computing	Microsoft Azure	1	\$44,000	\$44,000
Software	Machine Learning	TensorFlow	1	\$45,000	\$45,000
Software	Big Data	Hadoop	1	\$46,000	\$46,000
Software	Blockchain	Ethereum	1	\$47,000	\$47,000
Software	Cloud Computing	Amazon Web Services	1	\$48,000	\$48,000
Software	Machine Learning	TensorFlow	1	\$49,000	\$49,000
Software	Big Data	Hadoop	1	\$50,000	\$50,000
Software	Blockchain	Ethereum	1	\$51,000	\$51,000
Software	Cloud Computing	Microsoft Azure	1	\$52,000	\$52,000
Software	Machine Learning	TensorFlow	1	\$53,000	\$53,000
Software	Big Data	Hadoop	1	\$54,000	\$54,000
Software	Blockchain	Ethereum	1	\$55,000	\$55,000
Software	Cloud Computing	Amazon Web Services	1	\$56,000	\$56,000
Software	Machine Learning	TensorFlow	1	\$57,000	\$57,000
Software	Big Data	Hadoop	1	\$58,000	\$58,000
Software	Blockchain	Ethereum	1	\$59,000	\$59,000
Software	Cloud Computing	Microsoft Azure	1	\$60,000	\$60,000
Software	Machine Learning	TensorFlow	1	\$61,000	\$61,000
Software	Big Data	Hadoop	1	\$62,000	\$62,000
Software	Blockchain	Ethereum	1	\$63,000	\$63,000
Software	Cloud Computing	Amazon Web Services	1	\$64,000	\$64,000
Software	Machine Learning	TensorFlow	1	\$65,000	\$65,000
Software	Big Data	Hadoop	1	\$66,000	\$66,000
Software	Blockchain	Ethereum	1	\$67,000	\$67,000
Software	Cloud Computing	Microsoft Azure	1	\$68,000	\$68,000
Software	Machine Learning	TensorFlow	1	\$69,000	\$69,000
Software	Big Data	Hadoop	1	\$70,000	\$70,000
Software	Blockchain	Ethereum	1	\$71,000	\$71,000
Software	Cloud Computing	Amazon Web Services	1	\$72,000	\$72,000
Software	Machine Learning	TensorFlow	1	\$73,000	\$73,000
Software	Big Data	Hadoop	1	\$74,000	\$74,000
Software	Blockchain	Ethereum	1	\$75,000	\$75,000
Software	Cloud Computing	Microsoft Azure	1	\$76,000	\$76,000
Software	Machine Learning	TensorFlow	1	\$77,000	\$77,000
Software	Big Data	Hadoop	1	\$78,000	\$78,000
Software	Blockchain	Ethereum	1	\$79,000	\$79,000
Software	Cloud Computing	Amazon Web Services	1	\$80,000	\$80,000
Software	Machine Learning	TensorFlow	1	\$81,000	\$81,000
Software	Big Data	Hadoop	1	\$82,000	\$82,000
Software	Blockchain	Ethereum	1	\$83,000	\$83,000
Software	Cloud Computing	Microsoft Azure	1	\$84,000	\$84,000
Software	Machine Learning	TensorFlow	1	\$85,000	\$85,000
Software	Big Data	Hadoop	1	\$86,000	\$86,000
Software	Blockchain	Ethereum	1	\$87,000	\$87,000
Software	Cloud Computing	Amazon Web Services	1	\$88,000	\$88,000
Software	Machine Learning	TensorFlow	1	\$89,000	\$89,000
Software	Big Data	Hadoop	1	\$90,000	\$90,000
Software	Blockchain	Ethereum	1	\$91,000	\$91,000
Software	Cloud Computing	Microsoft Azure	1	\$92,000	\$92,000
Software	Machine Learning	TensorFlow	1	\$93,000	\$93,000
Software	Big Data	Hadoop	1	\$94,000	\$94,000
Software	Blockchain	Ethereum	1	\$95,000	\$95,000
Software	Cloud Computing	Amazon Web Services	1	\$96,000	\$96,000
Software	Machine Learning	TensorFlow	1	\$97,000	\$97,000
Software	Big Data	Hadoop	1	\$98,000	\$98,000
Software	Blockchain	Ethereum	1	\$99,000	\$99,000
Software	Cloud Computing	Microsoft Azure	1	\$100,000	\$100,000

